|Description||ALG1001, also known as Luminate, a first-in-class integrin peptide therapy, is an angiogenesis inhibitors and Integrin alpha 5 beta 1 modulator. A study from Johns Hopkins University also showed that ALG-1001 reduced vascular leakage.|
|Appearance||White to off-white solid powder|
|Synonyms||L-Proline, glycyl-L-arginylglycyl-3-sulfo-L-alanyl-L-threonyl-; ALG1001; ALG-1001; ALG 1001; Luminate; H-Gly-Arg-Gly-(L-Ala(SO3))-Thr-Pro-OH.|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
ATN-161 is a small peptide antagonist of integrin alpha5beta1 with potential antineoplastic activity. ATN-161 selectively binds to and blocks the receptor for i...
TCS 2314 is an integrin very late antigen-4 (VLA-4; α4β1) antagonist (IC50 = 4.4 nM) that inhibits the activation of inflammatory cells.
Zaurategrast is an oral α4-integrin inhibitor. It significantly decreased the capacity of lymphocytes to bind vascular adhesion molecule-1 (VCAM-1) and the expr...
ATN-161 trifluoroacetate salt
ATN-161 trifluoroacetate salt is a beta integrin antagonist with antitumor activity. It is a five -amino-acid peptide derived from the synergy region of fibrone...
SR121566A, a non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, has been shown to block platelet aggregation induced by a wide variety of agonists incl...
JNJ26076713 is an orally active alpha V integrin antagonist. It may be a potential therapeutic candidate for the treatment of age-related macular degeneration,p...
Obtustatin is an integrin α1β1 inhibitor with IC50 value of 0.8 nM for α1β1 binding to type IV collagen. Some research shows that it has antitumor efficacy in a...
BTT 3033 is a selective inhibitor of α2β1 integrin (EC50 = 130 nM for α2β1 binding to collagen I) that binds to the α2I domain. BTT 3033 inhibits platelet aggre...